HUMira for active hand OsteoaRthritis (HUMOR trial)

The HUMOR trial is a randomised crossover trial which will investigate the effect of a new treatment for a rare form of hand osteoarthritis known as erosive osteoarthritis. Each participant will receive both active drug and placebo one after the other, but in random order.

Osteoarthritis of the hand is a very common type of arthritis, and is usually not characterised by marked inflammation. However, erosive osteoarthritis is a rarer form of arthritis which involves more pain and inflammation, and is more difficult to treat than more typical nodal osteoarthritis. Given this lack of effective treatments and the disabling nature of this form of osteoarthritis, more novel therapeutic options are worth considering. We are trialling a treatment called adulimumab (Humira) which has been successfully used in inflammatory conditions such as rheumatoid arthritis. If Humira is effective in reducing pain and inflammation in people with erosive hand osteoarthritis, this will be a novel treatment for slowing progression of the disease in people with this type of hand osteoarthritis.

The aim of this study is to determine whether adalimumab 40 mg (given every other week) or placebo reduces pain and signs of inflammation compared to placebo in people with erosive hand osteoarthritis.

The recruitment phase of this study is now complete.Contact Laura.Laslett@utas.edu.au for more information.

This project is a participant based study

Research Groups

• Musculoskeletal: Jones & Ding Group

Related Diseases

• Osteoarthritis

Staff

Team Leaders

• Professor Graeme Jones

Team Members

• Dr Laura Laslett
• Margie Green
• Kate Butorac

External Collaborators

• Dr Paul Bird